BIOLINERX
Facebook
|
Twitter
|
Linkedin
| Careers | Contact Us
search

News release
BioLineRx Ltd. to Host Investor Breakfast in New York on December 3, 2015

TEL AVIV, Israel--(BUSINESS WIRE)--Nov. 25, 2015-- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it will host an investor breakfast on Thursday, December 3, 2015, in New York City.

At the breakfast, the Company will present the clinical development strategy for BL-8040, its lead oncology and hematology platform, for 2016 and beyond. The event will also include a keynote presentation by internationally-renowned key opinion leader, Dr. John DiPersio, Chief of the Division of Oncology at Washington University School of Medicine in St. Louis, entitled a “Review of the CXCR4 Landscape.”

Event Schedule:
8:00 a.m. -- 8:35 a.m.     Breakfast and registration
8:35 a.m. -- 9:45 a.m. Presentations
9:45 a.m. -- 10:00 a.m. Q&A
 
Location:
Convene, Bryant Park Hub
730 Third Avenue (between 45th and 46th Street)
New York, NY 10017
Tel: 646-854-7950
 

BioLineRx Ltd. will also host a live audio webcast of the investor breakfast. For access to the webcast, please go to the breakfast event page on BioLineRx’s website. It is recommended that users register 15 minutes prior to the scheduled start time to ensure timely connection. An audio replay of the meeting will also be available for approximately three months following the meeting on the breakfast event page.

Registration and Additional Information

Advanced registration is required for onsite attendance. To register, please contact Vivian Cervantes at vivian@pcgadvisory.com.

About BioLineRx

BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx’s current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-8040, a cancer therapy platform, which is in the midst of a Phase 2 study for relapsed/refractory AML, has recently initiated a Phase 2b study as an AML consolidation treatment, has recently initiated a Phase 1/2 study in hMDS and AA, and has successfully completed a Phase 1 study in stem cell mobilization; and BL-7010 for celiac disease, which has successfully completed a Phase 1/2 study.

In December 2014, BioLineRx entered into a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates. The companies intend to co-develop a number of pre-clinical and early clinical therapeutic projects through clinical proof-of-concept for potential future licensing by Novartis.

For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company’s SEC documents, press releases, and events. BioLineRx’s IR app is available on the iTunes App Store as well as the Google Play Store.

Various statements in this release concerning BioLineRx’s future expectations constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as “may,” “expects,” “anticipates,” “believes,” and “intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the “Risk Factors” section of BioLineRx’s most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 23, 2015. In addition, any forward-looking statements represent BioLineRx’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

Source: BioLineRx Ltd.

PCG Advisory
Vivian Cervantes, 212-554-5482
Investor Relations
vivian@pcgadvisory.com
or
for BioLineRx Ltd.
Tsipi Haitovsky, +972-3-624-0871
Public Relations
tsipihai5@gmail.com


Interview with Philip Serlin, CEO
December 2016